(RECEIVED FOR PUBLICATION JANUARY 6, 1953) Clinical trials of two drugs new to the American continent, phenylbutazone (Butazolidin) and butapyrin, were begun with the assumption that any beneficial effect from them in various rheumatic diseases would be chiefly that of producing analgesia. As the studies progressed it became apparent that the drugs had more than an analgesic action in acute gouty arthritis, that studies of butapyrin could be discontinued, and that the investigation could be focused on phenylbutazone.
"Butazolidin" is the trade name for phenylbutazone, a totally new compound originally used in Europe as a solubilizing agent for various analgesics given by intramuscular injection, notably for dimethylamino-antipyrin (aminopyrin). Butapyrin (marketed in some countries under the name of "Irgapyrin") is a simple mixture of equal parts of phenylbutazone and dimethylamino-antipyrin (Fig. 1) . A short bibliography of selected references in the literature to the use of these drugs is given below. Method of Investigation Phenylbutazone was given clinical trial in 51 patients with rheumatoid arthritis, thirteen with rheumatoid spondylitis, and sixteen with acute gouty arthritis. Experience with butapyrin was similar, but less extensive (Table I) . A critical comparison was made between the initial and subsequent observations of the patients investigated, from both the subjective and objective viewpoint. Repeated urine analyses were made on all patients in the early portion of the study. In cases where the degree of clinical improvement warranted it, the erythrocyte sedimentation rates were measured. In many cases of gout, the plasma and urinary uric acid were determined. Toxic.-The undesirable effects ("toxicity") found in this investigation were similar in nature for both drugs, but were more numerous with butapyrin-68 per cent. v. 26 a 7 per cent. (Table III) . Quite often the disturbances were sufficiently severe to require discontinuance of the drug. The most frequent and troublesome undesirable effects were nausea, anorexia, vomiting, epigastric pain, and diarrhoea, in that order of frequency. Erythematous dermatitis, patchy or generalized, and usually non-pruritic, sometimes necessitated discontinuance of the drug. One pharmacologic action of butapyrin is the production of sodium and water retention. Phenylbutazone may be largely responsible for this, because gain in weight invariably occurred when Butazolidin was administered. Observable oedema was less' frequent, and was rarely troublesome. Drowsiness was reported occasionally.
These undesirable effects, particularly the gastrointestinal disturbances, were sufficiently frequent to hamper our studies, and it was often necessary to discontinue the oral use of these drugs. Of fourteen $ Haematemesis thought to be due to diaphragmatic hernia (one patient). § Exacerbation of duodenal ulcer symptoms (one patient).
patients given phenylbutazone intramuscularly, none showed any gastro-intestinal disturbance, and one patient who had had a proven duodenal ulcer, tolerated parenteral phenylbutazone after its use orally had caused significant gastro-intestinal disturbance. The appearance of one or more of these undesirable effects was the chief reason for discontinuance of the drug in 20 per cent. of patients given phenylbutazone and in 68 per cent. of patients given butapyrin. Although it is possibly more effective as an analgesic agent, we discontinued our studies of butapyrin and focused our attention on phenylbutazone because the latter drug provided similar benefits, with fewer and less severe signs of toxicity.
The absorption of phenylbutazone from the gastro-intestinal tract was studied by using tablets which had different types of coating used in an effort to lessen or eliminate the nausea and indigestion. There was considerable difference in degree of absorption with the different types of tablets and the data is still inadequate to allow satisfactory selection to be made. The problem is being studied further in connection with determinations of phenylbutazone concentration in the blood and urine. 
Effects in Patients with Gout
The action of phenylbutazone in patients with gout deserves special attention because:
(1) it produces rapid and excellent clinical improvement in a high percentage of patients with acute gouty arthritis, (2) it affects the plasma udic acid levels. Sixteen patients with gout were studied through forty attacks of acute gouty arthritis. Of these attacks, 36 were treated with phenylbutazone (27 orally and 9 intramuscularly), and four with butapyrin. Thirty of these attacks were suppressed rapidly and completely, and there were ten treatment failures with oral phenylbutazone or butapyrin. Three of these occurred in patients who subsequently derived marked benefit from phenylbutazone intramuscularly. In four patients failures occurred at a time when Benemid was being administered simultaneously; two of these patients experienced the usual remarkable benefit from phenylbutazone during subsequent attacks-after administration of Benemid had been discontinued. Two patients had trials only with oral phenylbutazone and no opportunity presented to treat subsequent attacks with this medicine intramuscularly. One gouty patient had an excellent response to phenylbutazone given orally in the first attack, but later attacks failed to respond to the oral or intramuscular administration of the drug.
From these experiences it appears that:
(1) There may be some antagonistic action between Benemid and phenylbutazone, at least in some gouty patients. These two agents have quite different effects on uric acid metabolism, so that in some circumstances the beneficial effect of phenylbutazone may be prevented by Benemid.
( (Fig. 2) . In nine patients with uncontrolled diets there was no significant increase in output of urinary uric acid. This suggests that the decrease in plasma concentration of uric acid may not be due to a uricosuric action of this drug.
In thirteen non-gouty patients who had been receiving phenylbutazone, the average plasma uric acid value was I 8 mg. per cent. (the average in our laboratory for non-gouty patients is above 3 mg. per cent. Experiment 2.-Crystalline uric acid was added to the plasma of a patient who had received 200 mg. phenylbutazone by intramuscular injection 2 hrs before the blood specimen was obtained. A reading for uric acid was made on the original (control) plasma and on the plasma after the addition of crystalline uric acid. Aliquots of both control and test solutions were stored for 24 hrs at 370 C., at room temperature, and in a deep freeze. Again analyses showed no evidence thft the plasma contained any agent that lowered the uric acid value of an artificially produced "hyperuricaemic plasma" in vitro.
Experiment 3.-Increasing amounts of a solution of phenylbutazone were added to equal volumes of a standard uric acid solution. Readings of uric acid were made before and after the addition of phenylbutazone showed no significant change, regardless of the amount of drug added. This, again, indicates that phenylbutazone had no discernible effect on the uric acid content of solutions in vitro.
Experiment 4.-Specimens of normal plasma and plasma from patients receiving phenylbutazone were obtained and their plasma uric acid concentration was determined. The specimens were then mixed, and the uric acid content of the mixed solution was determined.
Aliquots control and solutions were stored at 370 C. for 24 hrs, and the uric acid content was again determined. No evidence was found that the "phenylbutazone plasma" could thus destroy plasma uric acid in vitro.
Summary
Clinical trials with phenylbutazone (Butazolidin) and butapyrin (Irgapyrin) were made in patients with rheumatoid arthritis, spondylitis, and gout. Phenylbutazone is a potent analgesic agent in certain patients with rheumatoid arthritis, and some tolerate it well and have derived benefit for as long as 9 months. Its oral use, however, is limited in some patients by undesirable side-effects, mostly gastrointestinal disturbances. Oedema is rarely a problem, but the drug is contraindicated in patients with a tendency to oedema due to cardiac, renal, or hepatic disease. Although no instances of blood dyscrasia were observed among our patients, precautions should be taken for their detection. Gastrointestinal symptoms were not observed when phenylbutazone was given intramuscularly, but irritation may occur at the site of injection, and the need for injections daily or every second day to sustain benefit makes this method of administration impractical in rheumatoid patients.
Very good clinical results from phenylbutazone were usually obtained in patients with rheumatoid spondylitis.
In patients with acute gouty arthritis, phenylbutazone usually gave rapid and dramatic results, often superior to those obtained with other agents (i.e. colchicine and corticotrophin). The suggested ability of phenylbutazone to lower the plasma uric acid without significant uricosuric effect is unique. This phenomenon must be studied more carefully; it may be a key to further understanding of the fundamental metabolic defect in gout.
Any additional benefit from the mixture of phenylbutazone and aminopyrin (butapyrin) is far outweighed by the greater incidence and severity of undesirable side-effects and by the hazards of administration.
Studies of the plasma concentration of phenylbutazone correlated with dosage and clinical results may help to decrease the undesirable side-effects and improve the value of this drug.
The phenylbutazone (Butazolidin) and butapyrin used in these investigations were generously supplied by Geigy Pharmaceuticals, Inc., N.Y., through the kindness of Dr. A. Hemming, to whom we express our appreciation and thanks. Addendum
Since this report was submitted for publication the authors have learned of one instance of aplastic anaemia and of four instances of granulopenia following administration of phenylbutazone (Stifel and Burnheimer, 1953; Bershof and Oxman, 1953) . Stifel, J. L., and Burnheimer, J. C. (1953 Estudios clinicos del fenilbutazone (Butazolidin) y de la butapirina (Irgapyrin) en la artritis reumatoide, la espondilitis reumatoide y en la gota SUMARIO Se hizo ensayos clinicos del fenilbutazone (Butazolidin) y de la butapirina (Irgapyrin) en enfermos con artritis reumatoide, espondilitis, y gota. El fenilbutazone es un analgesico poderoso en ciertos enfermos con artritis reumatoide; algunos le toleraron bien y le tomaron con provecho durante periodos que se extendian a veces hasta 9 meses. Sin embargo, efectos secundarios nocivos, ante todo disturbios gastro-intestinales, limitan su empleo por via oral. El edema es un problema poco frecuente, pero este producto no debe administrarse a enfermos con tendencia al edema cardiaco, renal o hepatico. Aunque no se hubiese encontrado casos de discrasia sanguinea entre los enfermos estudiados, es menester de buscarlos. Despues de la administraci6n intramuscular del fenilbutazone no se vieron disturbios gastrointestinales, pero una irritaci6n en el sitio de la inyecci6n puede aparecer, lo que reduce el valor practico de esta via, ya que se necesitan inyecciones diarias o cada dos dias para mantener la mejoria en los reumaticos.
Se obtuvieron generalmente muy buenos resultados con el fenilbutazone en casos de espondilitis reumatoide.
En casos de artritis gotosa aguda el fenilbutazone producia generalmente resultados rapidos y dramaticos, a veces superiores a los obtenidos con otros medicamentos (p. ej. colchicina y corticotrofina). El fenilbutazone tiene el poder aparente, que es excepcional, de hacer bajar la tasa del acido uirico del plasma sin producir un efecto uricos(irico significante. Este fen6-meno ofrece quizas la llave del problema del disturbio metab6lico fundamental en la gota.
Las ventajas de unb mezcla de fenilbutazone y de butapirina desaparecen frente a la mayor frecuencia y gravedad de los efectos secundarios y a los peligros posol6gicos. El estudio de las variaciones de la tasa sanguinea del fenilbutazone en correlaci6n con las dosis y los resultados clinicos podria contribuir a la reduccion de los efectos secundarios nocivos, aumentando asi el valor del medicamento.
